Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Ex #3 - Barda just gave SRI $ 90 MIL for testing capability

<< Previous

Bullboard Posts

Next >>

Comment by Looking4Doubleson Jun 11, 2020 2:38pm

63 Views

Post# 31139762

RE:RE:Ex #3 - Barda just gave SRI $ 90 MIL for testing capability

JMark80 wrote: That contract is 3 years old. Other two involve vaccines.

My point is that Barda does a LOT of things and the talk in the U.S. is for far-ranging efforts, NOT just vaccines

The OTHER TWO? - You need to RE-read them, not just the titles (one for Viles, one for packaging tech.)

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale